Ann: Telix Completes TLX250-CDx (Zircaix) BLA Submission, page-33

With respect to the financial benefits, EAPs can earn early revenues in the countries where early access through NPPs can be charged by the companies. EAPs can be immensely useful in early market penetration leading to increased acceptance and uptake by physicians and patients after the commercial launch of the product.



Fees are levied at each stage of the application and contrary to other countries such as the USA and France, the early access provided by the company through EAMS is free of cost.[16] Other countries where early access to medicines is provided free of cost include Austria, Germany, Greece, and Spain.